Promising Vaccine Shows Immune Response in Phase 1 Trial for Aggressive Triple-Negative Breast Cancer
A novel vaccine designed to prevent triple-negative breast cancer has demonstrated a significant immune response in early-stage clinical trials,offering a potential breakthrough in the fight against this aggressive disease. Presented by researchers at Cleveland Clinic, the phase 1 trial results indicate the investigational vaccine is both safe and capable of stimulating the immune system in a substantial proportion of participants.
Triple-negative breast cancer (
Promising Vaccine Shows immune Response in Phase 1 Trial for Aggressive Triple-Negative Breast Cancer
A novel vaccine targeting α-lactalbumin has demonstrated a significant immune response in a Phase 1 clinical trial conducted by Cleveland Clinic,offering a potential preventative strategy against the aggressive and often fatal triple-negative breast cancer. The trial,presented recently,revealed that 74% of participants exhibited an immune response to the investigational vaccine,alongside a favorable safety profile. This represents a crucial step forward in the development of preventative options for a subtype of breast cancer with limited treatment avenues.
Triple-negative breast cancer (TNBC) is known for its aggressive nature and higher incidence among Black women, making the development of preventative strategies particularly critical.Current treatment options are often limited due to the cancer’s lack of common receptors, hindering targeted therapies. This vaccine aims to address this unmet need by harnessing the body’s own immune system to fight the disease.
“The results from this trial are promising, as they suggest the investigational vaccine is not only safe and well tolerated but also capable of inducing immune responses in over 70% of participants,” stated G. Thomas Budd, MD, lead study investigator from Cleveland Clinic’s Cancer Institute.
Study Design and Diverse Patient Cohorts
The Phase 1 clinical trial (NCT04674306) was meticulously designed to assess both the safety and potential efficacy of the vaccine in preventing TNBC. Researchers enrolled 35 patients across three distinct cohorts, each representing a different clinical scenario. this multifaceted approach allows for a broader understanding of the vaccine’s potential impact across various risk profiles.
* Phase 1a: This cohort included 26 patients who had recently completed treatment for early-stage TNBC within the past three years and were currently tumor-free. Though, these individuals faced a significant risk of cancer recurrence.
* Phase 1b: Five patients with known genetic mutations predisposing them to an increased risk of breast cancer participated in this phase. These participants proactively chose to undergo preventative mastectomies in conjunction with the vaccine trial.
* Phase 1c: This cohort comprised patients currently undergoing neoadjuvant therapy – treatment
Keep reading